Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative bre...
Publications
2 shownTucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in b...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 2,525
- Institution
- Vall d'Hebron Institute of Oncology
External Links
Identifiers
- ORCID
- 0000-0001-9152-8799
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.